Abstract
Objectives This study aimed to identify pretreatment factors associated with skeletal muscle mass (SMM) loss during first-line chemotherapy in this population. Methods This single-centre retrospective study included 108 patients aged ≥70 years with diffuse large B-cell lymphoma (DLBCL) who completed first-line rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone or rituximab, cyclophosphamide, tetrahydropyranyl-adriamycin, vincristine, prednisone therapy. Skeletal muscle index (SMI, cm²/m²) was calculated by dividing the cross-sectional muscle area at the third lumbar vertebra on abdominal CT by height squared. The percentage SMI loss was derived from pretreatment and post-treatment measurements. Patients were dichotomised into SMI-loss and SMI-maintained groups using the median SMI loss (5.9%) as the cut-off. Logistic regression was performed using SMI loss as the dependent variable and pretreatment factors as predictors. A sensitivity analysis using the Firth correction was also conducted. Results Among the 108 patients, 54 (50%) were classified into each group. High pretreatment Glasgow Prognostic Score (GPS=2) independently predicted SMI loss (adjusted OR: 2.96; 95% CI 1.17 to 7.53; p=0.023). This association remained significant in the Firth-corrected model (OR: 1.59; 95% CI 1.01 to 2.58; p=0.041). Patients with high GPS more often exhibited B symptoms, elevated lactate dehydrogenase, poor International Prognostic Index scores, reduced performance status (PS) and low haemoglobin. Conclusions Pretreatment GPS may serve as a surrogate marker for SMM loss risk during first-line chemotherapy in elderly patients with DLBCL. Inflammation, malnutrition, reduced physical activity and poor PS may all contribute to SMM loss. Early exercise and nutritional interventions should be considered for patients with high GPS.
Keywords
Affiliated Institutions
Related Publications
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in adults, is a clinically and genetically heterogeneous disease that is further classified into trans...
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67
Abstract To assess the prognostic significance of the growth fraction in diffuse large cell lymphoma (DLCL), we studied 105 DLCL patients with the monoclonal antibody Ki-67 appl...
Management of Hepatocellular Carcinoma: An Update Δσ
Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new in...
Publication Info
- Year
- 2025
- Type
- article
- Pages
- spcare-2025
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1136/spcare-2025-005797
- PMID
- 41371761